I will now address the topic of my lecture: nutrition, genes and age-related macular degeneration (AMD). What have we learned from the recent trials? These study results are the culmination of the work conducted by many collaborators in the Age-Related Eye Disease Study (AREDS) and the AREDS2. I am grateful for their collaboration.
It is no doubt that we are indeed what we eat. The first clue that AMD may have association with dietary risk factors comes from the first National Health and Nutrition Examination Survey (NHANES) survey, which was published in 1988 [1] . Diets rich in fruits and vegetables with vitamins, especially vitamin A, were inversely associated with AMD. Since then, numerous studies have suggested the importance of dietary risk factors, and clinical trials were conducted to evaluate specific antioxidant vitamins and zinc.
The AREDS and AREDS2
The AREDS, a study supported by the National Institutes of Health, was designed to study the natural course of the age-related cataract and AMD. It also evaluated the nutritional risk factors, which began in 1992 as randomized controlled clinical trial assessing antioxidant vitamins C (500 mg), E (400 international units), and betacarotene (15 mg), and zinc (80 mg of zinc oxide) with copper (2 mg of cupric oxide). This was a factorial design with 3,640 participants randomized to placebo ( n = 903), antioxidants ( n = 945), zinc ( n = 904), and to the combination of antioxidants and zinc ( n = 888). In 2001, after a median follow-up of 6.5 years, the results of the study showed that the AREDS supplements were beneficial in reducing the risk of progression to late AMD by 25% [2] . This AREDS formulation was found to have persistent beneficial effects with 10 years of follow-up [3] .
Observational data from AREDS suggested that the increased dietary intake of lutein and zeaxanthin in green leafy vegetable such as kale, collard greens, and spinach, and omega-3 long-chain polyunsaturated fatty acids (LCPUFAs) found in fish were inversely associated with the risk of late AMD [4 , 5] . This was supported by other observational studies, such as population-based studies or other case-control studies [6] [7] [8] [9] [10] [11] .
Observational data cannot provide causal effects and can only determine associations. These associations may be due to other confounding factors. These suggested nutrients must be studied in a randomized controlled clinical trial to evaluate their potential therapeutic effects on AMD.
AREDS2 was designed to evaluate the effects of lutein/ zeaxanthin and omega-3 LCPUFAs on AMD [12] . Because the AREDS2 participants were at high risk of developing late AMD, the AREDS formulation would be recommended to them. The treatment effect of the additional nutrients, lutein/zeaxanthin and omega-3 LCPUFAs was evaluated as the effect beyond that of AREDS supplement, which is known to reduce the risk of progression to late AMD. The primary goal of AREDS2 was to determine whether adding lutein/zeaxanthin and/or docosahexaenoic acid/eicosapentaenoic acid (DHA/EPA) to the AREDS formulation decreases the risk of late AMD, defined as neovascular AMD or central geographic atrophy. A secondary objective is to evaluate the effect of eliminating beta-carotene and/or lowering zinc levels in the AREDS formulation.
The AREDS2 was a multicenter phase 3 randomized, double-masked, placebo-controlled trial conducted between 2006 and 2012, which enrolled participants, aged 50-85 years, at risk for progression to AAMD. The primary randomization included the daily AREDS supplement plus one of the following: lutein/zeaxanthin (10/2 mg), DHA/EPA (350/650 mg), a combination of these 2, or placebo. The secondary randomization consisted of the elimination of beta-carotene and/or lowering of zinc to 25 mg instead of the original 80 mg found in the AREDS formulation. Both were factorial designs. The major outcome measurement was the development of late AMD, either neovascular AMD or central geographic atrophy, as documented by centralized grading of annual retinal photographs and by treatment history.
Results of the AREDS2
In 82 academic and community centers across the United States, 4,203 participants with either bilateral large drusen or large drusen in 1 eye with late AMD in the fellow eye were enrolled. Population characteristics at baseline were as follows: mean (standard deviation) age 73.1 (7.7) years, 57% female, 97% white, 7% current smokers, 19% with prior cardiovascular disease, and 44 and 50% taking statin-class cholesterol-lowering drugs and aspirin, respectively. About two-thirds of the participants had bilateral large drusen or less severe, and one-third had advanced AMD in 1 eye and a mean visual acuity of 20/32 in eyes without advanced AMD. They were followed for a median of 4.9 years (interquartile range: 4.3, 5.1). Three percent were lost to follow-up, and 9% died. Compliance was good with 85% of the participants taking 75% of their study supplements.
The primary analyses compared each of the treatment groups with placebo, and there were no statistically significant differences [13] . However, when using the entire population in the evaluation comparing lutein/zeaxanthin versus no lutein/zeaxanthin in the so-called main effects analyses that doubled the sample size, there was a 10% reduction in the risk developing advanced AMD (hazard ratio In analyses restricted to those with bilateral large drusen at baseline, the HRs for lutein/zeaxanthin versus no lutein/zeaxanthin were 0.87 (95% CI: 0.77-0.95, p = 0.04) for developing late AMD; 0.80 (95% CI: 0.68-0.95, p = 0.01) for progression to neovascular AMD, and 0.94 (95% CI: 0.78-1.13, p = 0.51) for progression to central geographic atrophy.
Another interesting analysis was the comparison of lutein/zeaxanthin plus beta-carotene versus beta-carotene alone, showing a HR of 0.82 (95% CI: 0.69-0.97, p = 0.02) for the development of late AMD. This same analysis for the development of neovascular AMD showed a HR of 0.72 (95% CI: 0.59-0.89, p = 0.002). This suggests that the effects are driven by lutein/zeaxanthin and that beta-carotene has a minimal role.
Individuals randomized to beta-carotene had double the risk of lung cancer (2 vs. 0.9%), p = 0.04; 91% of the incident lung cancers were in former smokers. This suggests that beta-carotene has evidence of harmful effects in past smokers. For these reasons, the AREDS2 supplements, which replaced the beta-carotene with lutein and zeaxanthin, is preferred.
The main effects analyses of low zinc (25 mg as zinc oxide) versus high zinc (80 mg as zinc oxide) showed no difference in the primary outcome of progression to late AMD or adverse effects. These were not considered noninferiority analyses as we were not sufficiently powered or designed for such analyses. Therefore, we were not able to conclude that the 2 doses be similar in effect. Because of data from the original AREDS, which was a placebocontrolled trial demonstrating the beneficial effects of 80 mg of zinc, it was decided that AREDS2 supplement would continue to maintain 80 mg of zinc.
AREDS2 Cardiovascular Outcome Study
The AREDS Cardiovascular Outcome Study (COS) [15] was an ancillary study designed to evaluate the role of supplementation with DHA/EPA (350/650 mg) or lutein/zeaxanthin (10/2 mg) in reducing the risk of cardiovascular disease. The primary outcome was a composite outcome of myocardial infarction, stroke, and cardiovascular death. We also had prespecified secondary combinations of the primary outcome with hospitalized heart failure, revascularization, or unstable angina.
The results showed that a total of 602 cardiovascular events were adjudicated by an expert panel, and 459 were found to meet the criteria that were defined as an outcome. Using an intention-to-treat analysis, there was no reduction in the risk of cardiovascular disease or secondary cardiovascular outcomes for DHA plus EPA with HR: 0.95, 95% CI: 0.78-1.17 or for lutein/zeaxanthin with HR 0.94, 95% CI: 0.77-1.15. There were no differences in the adverse effects by treatment group. We had 80% power to detect a 25% reduction in the cardiovascular events.
We concluded that despite numerous epidemiologic evidence of the beneficial effect of consuming fish, oral supplementation of DHA and EPA or lutein/zeaxanthin did not reduce the risk of cardiovascular disease in these participants with evidence of AMD.
AREDS2 Cognitive Function Study
We also evaluated the role of oral supplements with DHA plus EPA and lutein/zeaxanthin for cognitive function in the AREDS2 population [16] as epidemiologic data suggested that high dietary intake of saturated fat and low intake of fruits and vegetables may be associated with an increased risk of impaired cognitive function. Several validated cognitive function tests were administered to the AREDS2 participants by telephone by certified examiners at baseline and every 2 years during the 5-year study. The primary outcome of this AREDS2 ancillary study was the yearly change in the composite score determined from the battery of cognitive function test from baseline. While adjusted for baseline age, race, sex, hypertension, education, cognitive score, and depression score, we analyzed the differences in the composite scores between the treated versus the untreated groups in AREDS2.
The results of the 3,741/2,403 (89%) of the AREDS2 participants who enrolled in this ancillary study showed no statistically significant differences in the change of scores for the participants assigned to receive the supplements versus those who were assigned to not receive the supplements. The changes in composite cognitive function score ranged from -22 to 17, with the better cognitive function represented by the high numeric score. The yearly change in the composite cognitive function score was -0.19 (99% CI: -0.25 to -0.13) for the AREDS2 participants assigned to receive DHA+EPA versus -0.18 (99% CI: -0.24 to -0.12) for those assigned to no DHA+EPA. The yearly change between the 2 treatment groups were not statistically significantly different (difference in yearly change, -0.03 [99% CI: -0.20 to 0.13], p = 0.63). The same was true for the lutein/zeaxanthin treatment arm as well. For those randomized to receive lutein/zeaxanthin, the yearly change in the composite cognitive function score was -0.18 (99% CI: -0.24 to -0.11) versus -0.19 (99% CI: -0.25 to -0.13) for those randomized to no lutein/zeaxanthin (difference in yearly change, 0.03 [99% CI: -0.14 to 0.19], p = 0.66). We concluded that despite the epidemiologic data support, the beneficial role of consuming omega-3 fatty acids in fish, oral supplementation with DHA+EPA, and lutein/zeaxanthin in persons with at least intermediate AMD did not have a beneficial or harmful effect.
Genetic Testing prior to Supplementing with AREDS2 Supplements
Previous reports suggested that genetic testing for AMD may have a role because of potential harmful genetic interaction with specifically the zinc component in the AREDS supplements [17 , 18] . Following the publication of differing opinions [19] , other genetic, statistical, and epidemiologic experts [20 , 21] and a panel of experts from the American Society of Retinal Surgeons (ASRS) weighed in [22] . They all supported the recommendations of the American Academy of Ophthalmology that genetic testing for AMD should not be conducted prior to considering treatments for AMD such as the AREDS supplements [23] .
Summary
The results of the epidemiologic and clinical trials have pointed to the importance of nutritional factors in AMD, cardiovascular disease, and cognitive function. Although the clinical trials did not show a beneficial effect of supplementation with omega-3 fatty acids in these 3 diseases, eating fish seemed to be important in many epidemiologic studies. In addition to maintaining a healthy lifestyle of weight control and eliminating tobacco use, persons at risk for AMD or who have intermediate AMD or worse should consider a diet replete with fish and green leafy vegetables. For potential beneficial effects, fish may be important for cardiovascular disease as well as cognitive function. The AREDS and AREDS2 supplements are also recommended for persons with at least intermediate AMD or late AMD in 1 eye. AREDS2 is safe, especially for smokers and former smokers who are at risk for developing lung cancer. Removing beta-carotene has reduced that risk. Genetic testing prior to AMD treatments, especially with AREDS/AREDS2 supplements, is not recommended by the American Academy of Ophthalmology and other organizations.
